Jad Othman

27PUBLICATIONS
164CO-AUTHORS
Gene and molecular therapyMedical virologyMedical mycologyMedical infection agents (incl. prions)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 04, 2026
ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

|Dec 15, 2025
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Jacqueline Cloos, Peter J M Valk, Christian Thiede

|Sep 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Nigel Russell, Jad Othman, Oliver Cumming

|Aug 06, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Jad Othman, Nicola Potter, Sylvie D Freeman

|Jul 03, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard

Pageof 5

Frequent Collaborators

10 joint publications

Richard Dillon

9 joint publications

Nicola Potter

8 joint publications

Sylvie D Freeman

6 joint publications

Ing Soo Tiong